WO2024023843 - A PHARMACEUTICAL FORMULATION OF A THERAPEUTICANTIBODY AND PREPARATIONS THEREOF
National phase entry is expected:
Publication Number
WO/2024/023843
Publication Date
01.02.2024
International Application No.
PCT/IN2023/050715
International Filing Date
26.07.2023
Title **
[English]
A PHARMACEUTICAL FORMULATION OF A THERAPEUTICANTIBODY AND PREPARATIONS THEREOF
[French]
FORMULATION PHARMACEUTIQUE D'UN ANTICORPS THÉRAPEUTIQUE ET SES PRÉPARATIONS
Applicants **
DR. REDDY’S LABORATORIES LIMITED
Inventors
JAYARAMAN, Murali
CHANDRAN, Anushri
SONI, Siddharth
MARIKANTY, Ravi Kumar
RAJARAMAN, Sucheta
Priority Data
202241042848
26.07.2022
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
IP India
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1951 | |
| EPO | Filing, Examination, Granting | 11536 | |
| Japan | Filing, Examination, Granting | 2024 | |
| South Korea | Filing, Examination, Granting | 1760 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
22,011
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention relates to pharmaceutical formulations of anti-CD38 antibodies. In particular, the invention discloses a composition stabilizing the antibodies from its lower to higher concentration. The stable composition thus obtained can be formulated as intravenous and subcutaneous formulations with the desired antibody concentrations enabling therapeutic use. The prepared composition, additionally controls fragmentation of the antibody during storage.[French]
La présente invention concerne des formulations pharmaceutiques d'anticorps anti-CD38. En particulier, l'invention concerne une composition stabilisant les anticorps contre leur concentration inférieure à plus élevée. La composition stable ainsi obtenue peut être formulée sous forme de formulations intraveineuses et sous-cutanées avec les concentrations d'anticorps souhaitées, permettant une utilisation thérapeutique. La composition préparée régule en outre la fragmentation de l'anticorps pendant le stockage.